Alnylam Pharmaceuticals
ALNY
236 hedge funds and large institutions have $10.3B invested in Alnylam Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 68 increasing their positions, 85 reducing their positions, and 33 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 8 → 12 (+4)
48% more capital invested
Capital invested by funds: $6.95B → $10.3B (+$3.33B)
36% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 33
21% more call options, than puts
Call options by funds: $392M | Put options by funds: $323M
4% more funds holding
Funds holding: 227 → 236 (+9)
0.09% more ownership
Funds ownership: 95.35% → 95.45% (+0.09%)
20% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 85
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$162M |
| 2 |
BlackRock
New York
|
+$78.8M |
| 3 |
O
OrbiMed
New York
|
+$38M |
| 4 |
Goldman Sachs
New York
|
+$24.1M |
| 5 |
D.E. Shaw & Co
New York
|
+$21.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
-$49M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$48.5M |
| 3 |
RI
RTW Investments
New York
|
-$35.6M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$34.3M |
| 5 |
BM
Bridger Management
New York
|
-$32M |
ALNY Hedge Fund Activity: Q3 2017 in Review
236 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2017, worth a combined $10.3B — up 48% from $6.95B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new ALNY positions and 33 closed out — a net gain of 12 holders — while 68 added to existing stakes and 85 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $162M. The largest seller was Slate Path Capital, cutting an estimated $49M.
- 236 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2017, up from 227 in Q2 2017.
- Funds reported $10.3B of Alnylam Pharmaceuticals stock for Q3 2017, up 48% quarter-over-quarter.
- 45 funds opened new Alnylam Pharmaceuticals positions in Q3 2017 and 33 closed out, a net change of +12 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2017 was T. Rowe Price Associates, an estimated $162M added.
- The largest Alnylam Pharmaceuticals seller in Q3 2017 was Slate Path Capital, an estimated $49M sold.
Based on aggregated 13F filings for Q3 2017.